For further information see here for the RNS.
Partner, Rob Wood, led the Osborne Clarke team assisted by Senior Associate Caroline Drummond.
Rob Wood comments:
“This is a significant deal in the Life Science sector, and it’s likely to be one of the top five private company funding rounds in 2014”.
Earlier this year, Osborne Clarke advised Imperial Innovations, Invesco Perpetual and others on the £581m IPO of the biopharmaceutical company, Circassia.
Share
Corporate communications and press contacts
If you are a journalist and would like comment or background from our legal experts, we can help. Our team will put you in touch with the best person. View a full list of our international press contacts by jurisdiction here.
